SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Yu LP, Smith GN, Hasty KA, Brandt KD. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991; 18: 14502.
  • 2
    Smith GN Jr, Brandt KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 1996; 39: 23544.
  • 3
    Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996; 93: 140149.
  • 4
    Lotz M. The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am 1999; 25: 26982.
  • 5
    Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983; 18: 51626.
  • 6
    Yu LP Jr, Smith GN Jr, Brandt KD, Myers SL, O'Connor BL, Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992; 35: 11509.
  • 7
    Smith G Jr, Yu L Jr, Brandt K, Capello W. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol 1998; 25: 5325.
  • 8
    Greenwald RA. Treatment of destructive arthritis disorders with MMP inhibitors. Ann N Y Acad Sci 1994; 731: 18198.
  • 9
    Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Kawai P, Hamasaki T, et al, inventors. Method to reduce connective tissue destruction. US patent 5,258,371. 1993 Nov 3.
  • 10
    Spector TD, Hart DJ, Doyle DV. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis 1994; 53: 5658.
  • 11
    Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 103949.
  • 12
    Kellgren JH, Lawrence JS. Radiographic assessment of osteoarthritis. Ann Rheum Dis 1956; 16: 494502.
  • 13
    National Health and Nutrition Examination Survey II: vital and health statistics anthropometric reference data and prevalence of overweight. US Dept. of Health and Human Services; Oct 1987. p. 212. Publication #PHS 87-1688.
  • 14
    Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 1987; 8: 1239.
  • 15
    Lang JM. The use of a run-in to enhance compliance. Stat Med 1990; 9: 8795.
  • 16
    Rudd P, Ahmed S, Szchary V, Barton C, Bonduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 67685.
  • 17
    Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 32737.
  • 18
    Buckland-Wright JC, Macfarlane DG, Williams SA, Ward RJ. Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Ann Rheum Dis 1995; 54: 87280.
  • 19
    Carson WG Jr, James SL, Larson RL, Singer KM, Winternitz WW. Patellofemoral disorders: physical and radiographic evaluation. II. Radiographic examination. Clin Orthop 1984; 185: 17886.
  • 20
    Lequesne M. Quantitative measurements of joint space during progression of osteoarthritis: chondrometry. In: KuettnerK, GoldbergV, editors. Osteoarthritic disorders. Rosemont (IL): American Academy of Orthopaedic Surgeons; 1995. p. 42744.
  • 21
    Mazzuca SA, Brandt KD, Buckwalter KA, Lequesne M. Pitfalls in the accurate measurement of joint space narrowing in semiflexed, anteroposterior radiographic imaging of the knee. Arthritis Rheum 2004; 50: 250815.
  • 22
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 23
    Physicians' desk reference. Montvale (NJ): Thomson PDR; 2004.
  • 24
    Schluchter MD. Methods for the analysis of informatively censored longitudinal data. Stat Med 1992; 11: 186170.
  • 25
    Schluchter MD, Greene T, Beck GJ. Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease. Stat Med 2001; 20: 9891007.
  • 26
    Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48: 3707.
  • 27
    Listrat V, Ayral X, Patarnello F, Bonvarlet JP, Simonnet J, Amor B, et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage 1997; 5: 15360.
  • 28
    Jubb RW, Piva S, Beinat L, Dacre J, Gishen P. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract 2003; 57: 46774.
  • 29
    McAlindon TE, Felson DT, Zhang Y, Hannan MT, Aliabadi P, Weissman B, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996; 125: 3539.
  • 30
    McAlindon TE, Jacques P, Zhang Y, Hannan MT, Aliabadi P, Weissman B, et al. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum 1996; 39: 64856.
  • 31
    Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 2516.
  • 32
    Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double blind study. Arch Intern Med 2002; 162: 211323.
  • 33
    Mazzuca SA, Brandt KD, German C, Buckwalter KA, Lane KA, Katz BP. Development of radiographic changes of osteoarthritis in the “Chingford knee” reflects progression of disease or non-standardized positioning of the joint, rather than incident disease. Ann Rheum Dis 2003; 62: 10615.
  • 34
    Archer GL, Polk RE. Treatment and prophylaxis of bacterial infections. In: FauciAS, BraunwaldE, IsselbacherKJ, WilsonJD, MartinJB, KasperDL, et al, editors. Harrison's principals of internal medicine. 14th ed. New York: McGraw-Hill; 1998. p. 85669.
  • 35
    Cole AA, Chubinskaya S, Luchene LJ, Chlebek K, Orth MW, Greenwald RA, et al. Doxycycline disrupts chondrocyte differentiation and inhibits cartilage matrix degradation. Arthritis Rheum 1994; 37: 172734.
  • 36
    Mazzuca SA, Brandt KD, Katz BP, Lane KA, Bradley JD, Heck LW, et al. Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. Arthritis Rheum 2004; 51: 93340.
  • 37
    Brandt KD. Disease-modifying osteoarthritis drugs (DMOADs): the clinical perspective. In: BrandtKD, DohertyM, LohmanderLS, editors. Osteoarthritis. 2nd ed. Oxford: Oxford University Press; 2003. p. 4019.
  • 38
    Squires GR, Okouneff S, Ionescu M, Poole AR. The pathobiology of focal lesion development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis. Arthritis Rheum 2003; 48: 126170.
  • 39
    Aigner T, Zien A, Hanisch D, Zimmer R. Gene expression in chondrocytes assessed with use of microarrays. J Bone Joint Surg Am 2003; 85 Suppl 2: 11723.
  • 40
    Doherty NS, Griffiths RJ, Pettipher ER. The role of animal models in the discovery of novel disease-modifying osteoarthritis drugs (DMOADS). In: BrandtKD, DohertyM, LohmanderLS, editors. Osteoarthritis. 1st ed. Oxford: Oxford University Press; 1998. p. 43949.
  • 41
    Pham T, van der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, et al, and OMERACT-OARSI. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria [review]. J Rheumatol 2003; 30: 164854.
  • 42
    Strand V, Kelman A. Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheumatol Rep 2004; 6: 2030.
  • 43
    Ayral X, Dougados M, Listrat V, Bonvarlet JP, Simonnet J, Amor B. Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J Rheumatol 1996; 26: 11407.